Emergent buys ABEC bioreactor to transfer raxibacumab to Baltimore facility

By Gareth Macdonald 

Bioterrorism countermeasure manufacturer Emergent Biosciences has bought a 4,000L bioreactor developed by ABEC.

Read the article.

 

 

ABEC breaks the 2,000L ‘plastic ceiling’ with 4,900L single-use bioreactor

 By Dan Stanton

ABEC says its latest offering has twice the working volume of the 2,000L bioreactor systems generally deemed to be the upper limit in single-use bioprocessing.

Read the article.